CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation
Cancer Letters · 2025-10 · 630 · 217898
DOI: 10.1016/j.canlet.2025.217898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-10. Verfasst von Na Yao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shangha…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Hyaluronic Acid, Extracellular Matrix, Pancreatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) ranks as third leading cause of cancer-related mortality, with chemoresistance progression driven by the desmoplastic extracellular matrix (ECM). Hyaluronic acid (HA), one of the major components of ECM, is notably enriched in PDAC. HA-based strategies, like lowering HA levels with a hyaluronidase, are worthy of experimental evidence for PDAC. Our previous work identified CEMIP2 (Cell migration inducing hyaluronidase 2) as a proteomic biomarker predictive of adjuvant chemotherapy response in PDAC, though its mechanistic role remains unclear. Herein, we observed that elevated CEMIP2 expression correlates with improved patient response to neoadjuvant and adjuvant chemotherapy. Using PDAC murine models, we reveal that CEMIP2 enhances gemcitabine efficacy through HA-dependent mechanisms involving drug delivery potentiation and vascular density modulation, attributable to its HA-degrading capacity. Consistent with this, CEMIP2 expression shows an inverse correlation with HA levels in clinical PDAC specimens, while low HA levels themselves associate with favorable treatment response and survival outcomes. Single-cell RNA sequencing (scRNA-seq) uncovered that CEMIP2 knockdown alters the tumor microenvironment (TME) by expanding cancer-associated fibroblast (CAF) populations. Both inflammatory (iCAF) and myofibroblast (myCAF) subtypes exhibited SPP1-CD44-mediated crosstalk with PDAC cells. Additionally, cytometry by time-of-flight (CyTOF) revealed that CEMIP2 depletion modulates the abundance and functional states of immune subsets, particularly tumor-associated macrophages (TAMs) and T cell populations. Collectively, our findings establish CEMIP2 as a critical regulator of chemotherapy response that reprograms the TME through HA degradation and ECM remodeling, providing novel insights into PDAC treatment resistance mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Pancreatic Neoplasms Translational Medicine, Shang…
- Department of General Surgery, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, China.
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yao, N., Fu, Y., Wang, T., Qin, J., Cao, Y., Shi, M., Ma, F., Shen, B., & Jiang, L. (2025). CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Cancer Letters, 630, 217898. https://doi.org/10.1016/j.canlet.2025.217898
Vancouver
Yao N, Fu Y, Wang T, Qin J, Cao Y, Shi M, et al. CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Cancer Letters. 2025;630:217898. doi:10.1016/j.canlet.2025.217898
BibTeX
@article{Yao2025,
author = {Yao, Na and Fu, Yue and Wang, Ting and Qin, Jiejie and Cao, Yizhi and Shi, Minmin and Ma, Fangfang and Shen, Baiyong and Jiang, Lingxi},
title = {CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation},
journal = {Cancer Letters},
year = {2025},
volume = {630},
pages = {217898},
doi = {10.1016/j.canlet.2025.217898}
}
EUVIMED